Aalberts, Noelle
Westhall, Erik
Johnsen, Birger
Hahn, Katrin
Kenda, Martin
Cronberg, Tobias
Friberg, Hans
Preuß, Sandra
Ploner, Christoph J.
Storm, Christian
Nee, Jens
Leithner, Christoph
Endisch, Christian http://orcid.org/0000-0003-2264-1821
Funding for this research was provided by:
Laerdal Foundation for Acute Medicine (2021-0067, 2021-0040)
Berlin Institute of Health
Charité - Universitätsmedizin Berlin
Article History
Received: 26 June 2023
Revised: 14 August 2023
Accepted: 17 August 2023
First Online: 28 August 2023
Declarations
:
: KH received financial reimbursement for consulting, advisory board activities, speaker fees and contributions to congresses and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc. and Swedish Orphan Biovitrum Inc. KH further received research funding by the foundation Charité (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. KH declared that none of this is related to the manuscript. JN reported receiving personal fees for consultancy and speaker fees from BD Bard. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: Local ethics committees fully approved this study and waived the need for patient consent (EA4/004/14). The study was conducted according to the Declaration of Helsinki.